MedTrace Logo

Drug Sensitivity and Mutation Profiling

NCT04956198 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2023-02-14

No results posted yet for this study

Summary

This study is a prospective, non-randomized observational study. Freshly isolated tumor cells will be tested for chemosensitivity to the standard of care drugs as single agents and in combinations using state-of-the-art viability assay designed for ex-vivo high-throughput drug sensitivity testing (DST). In addition, the genetic profile of the tumor will be obtained from the medical records and correlated with drug response.

Conditions

  • Ewing Sarcoma
  • Osteosarcoma
  • Rhabdomyosarcoma
  • Wilms Tumor
  • Sarcoma, Spindle Cell
  • Sarcoma Rhabdoid
  • Childhood Sarcoma of Soft Tissue

Sponsors & Collaborators

  • Nicklaus Children's Hospital f/k/a Miami Children's Hospital

    collaborator OTHER

  • Cornelia T. Bailey Foundation

    collaborator UNKNOWN

  • Florida International University

    lead OTHER

Principal Investigators

  • Diana Azzam, PhD · Florida International University

  • Daria Salyakina, PhD · Nicklaus Children's Hospital

  • Maggie Fader, MD · Nicklaus Children's Hospital

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-17
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04956198 on ClinicalTrials.gov